AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Ceapro Inc. Regulatory Filings 2021

Sep 8, 2021

44617_rns_2021-09-08_b3fabc6f-47b9-4cb1-a7aa-3c21a52ce91e.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

==> picture [109 x 42] intentionally omitted <==

Ceapro Inc. to Present at H.C. Wainwright 23rd Annual Global Investment Conference

EDMONTON, Alberta, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at the virtual H.C. Wainwright 2 3[rd] Annual Global Investment Conference taking place September 13-15, 2021.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be available for viewing on-demand beginning Monday, September 13, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (www.ceapro.com). The webcast replay will be archived for 90 days following the event.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas JTC Team, LLC Investor Relations and Corporate Communications Advisor T (US): +1 (833) 475-8247

E: [email protected]